Burzynski: Institutional Review Board (IRB)

http://www.burzynskiclinic.com/scientific-publications.html
� � � � � � � � � � � � � � � � �
Interim Reports on Clinial Trials:
�
16. 2003
�
DRUGS IN R&D
Drugs in R and D
(Drugs in Research and Development)
�
BT-11
BRAIN STEM GLIOMA
�
Phase II study of antineoplaston A10 and AS2-1 in patients with recurrent diffuse intrinsic BRAIN STEM GLIOMA:
�
a preliminary report.
http://www.ncbi.nlm.nih.gov/pubmed/12718563
Burzynski, S.R., Lewy, R.I., Weaver, R.A., Axler, M.L., Janicki, T.J., Jurida, G.F., Paszkowiak, J.K., Szymkowski, B.G., Khan, M.I., Bestak, M.
http://www.ncbi.nlm.nih.gov/m/pubmed/12718563
Drugs R D. 2003;4(2):91-101
Drugs in R&D 2003;4:91-101

Click to access 960.pdf

Pg. 93
�
Membership of the Institutional Review Board (IRB) was in agreement with the Food and Drug Administration (FDA).
� � � � � � � � � � � � � � � � �
Review Articles on Clinical Trials:
�
1. 3/2004
�
Burzynski, S.R. The Present State of Antineoplaston Research. Integrative Cancer Therapies 2004;3:47-58.

Click to access 994.pdf

Volume 3 Number 1 March 2004
DOI: 10.1177/1534735403261964
�
Pg. 55
�
Membership of the Institutional Review Board (IRB) was in agreement with the Food and Drug Administration (FDA).
� � � � � � � � � � � � � � � � �
Case Reports:
�
4. 9/2004
�
INTEGRATIVE CANCER THERAPIES
�
Special exception (SE) to BT-11
�
BRAIN STEM GLIOMA
�
Burzynski, S.R., Lewy, R.I., Weaver, R., Janicki, T., Jurida, G., Khan, M., Larisma, C.B., Paszkowiak, J., Szymkowski, B.
�
Long-term survival and complete response of a patient with recurrent diffuse intrinsic brain stem GLIOBLASTOMA MULTIFORME

Click to access 1145.pdf

Integrative Cancer Therapies 2004;3:257-261
Volume 3, Number 3 September 2004
DOI: 10.1177/1534735404267748
�
Pg. 258
�
Membership of the Institutional Review Board (IRB) was in agreement with the Food and Drug Administration (FDA).
� � � � � � � � � � � � � � � � �
Interim Reports on Clinial Trials:
�
17. 2004
�
DRUGS IN R&D
Drugs in R and D
(Drugs in Research and Development)
�
Burzynski, S.R., Weaver, R., Lewy, R., Janicki, T. Jurida, G., Szymkowski, B., Khan, M., Bestak, M.
�
Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma.
�
A Preliminary Report.
http://www.ncbi.nlm.nih.gov/pubmed/15563234
Drugs R&D 2004;5(6):315-326.
http://www.ncbi.nlm.nih.gov/m/pubmed/15563234
Drugs R D. 2004;5(6):315-26

Click to access 1194.pdf

Pg. 317
�
Membership of Institutional Review Board (IRB) was in compliance with FDA guidelines
� � � � � � � � � � � � � � � � �
Interim Reports on Clinial Trials:
�
18. 6/2005
�
INTEGRATIVE CANCER THERAPIES
�
BT-12
�
CHILDREN WITH PRIMITIVE NEUROECTODERMAL TUMORS (PNET)
�
CAN-01
�
CAN-1
�
PATIENTS WITH REFRACTORY MALIGNANCIES
�
Burzynski, S.R., Weaver, R.A., Janicki, T., Szymkowski, B., Jurida, G., Khan, M., Dolgopolov, V.
�
Long-term survival of high-risk pediatric patients with PRIMITIVE NEUROECTODERMALTUMORS treated with Antineoplastons A10 and AS2-1
http://www.ncbi.nlm.nih.gov/pubmed/15911929
Integrative Cancer Therapies 2005;4(2):168-177
http://www.ncbi.nlm.nih.gov/m/pubmed/15911929
Integr Cancer Ther. 2005 Jun;4(2):168-77

Click to access 1220.pdf

DOI: 10.1177/1534735405276835
http://m.ict.sagepub.com/content/4/2/168.long?view=long&pmid=15911929
Pg. 169
�
Membership of the Institutional Review Board (IRB) was in agreement with the Food and Drug Administration (FDA).
� � � � � � � � � � � � � � � � �

Advertisement